Next-Generation Sequencing (NGS) Innovations in Genotyping

The introduction of next-generation sequencing (NGS) has brought a major transformation to the human leukocyte antigen diagnostic field. Legacy sequencing techniques, such as Sanger sequencing, often generated ambiguous result calls due to phase ambiguity, where phase connections between polymorph sites across heterozygous DNA samples could not be resolved without secondary testing. NGS platforms overcome these limitations by executing clonal single-molecule sequencing, delivering complete, phase-defined allele sequences across all major HLA gene loci in a single workflow.

According to a recent report by Wise Guys Report, NGS-based testing platforms represent the fastest-growing technology segment in the HLA Typing Market, expanding at a double-digit CAGR. High-resolution NGS typing eliminates the need for expensive secondary reflex testing, significantly shortening pre-transplant workup schedules for patients awaiting stem cell or kidney transplants. Furthermore, high-throughput benchtop sequencers allow clinical laboratories to multiplex hundreds of donor samples simultaneously, dramatically reducing cost-per-sample metrics for large bone marrow registry screening programs.

In addition, long-read sequencing technologies are further enhancing structural characterization across complex genomic regions. By spanning entire gene loci including non-coding intronic sequences, long-read platforms provide unmatched resolution. As sequencing costs continue to fall, NGS will solidify its position as the definitive standard for clinical tissue matching.

Frequently Asked Questions (FAQs)

Q1: What is "phase ambiguity" in traditional HLA sequence analysis?

Phase ambiguity occurs when sequencing cannot determine which genetic variations reside on which chromosome, often requiring secondary testing to resolve allele identity.

Q2: How does next-generation sequencing (NGS) eliminate phase ambiguity?

NGS sequences individual single DNA molecules clonally, providing complete, phase-defined sequences across full gene loci in a single test run.

Q3: Why is NGS particularly advantageous for bone marrow donor registries?

NGS enables high-throughput sample multiplexing, allowing registries to screen thousands of volunteer donors simultaneously at a lower cost per sample.